Cord Blood Banking Market Growth

The first successful umbilical cord blood transplant was performed in 1988 by Dr. Elaine Gluckman, treating a patient with Fanconi anemia. Since then, over 40,000 such transplants have been conducted globally to treat more than 80 different diseases. The market is divided into private and public banks. Private banking, for a family's exclusive use, costs between $1,500 and $3,000 upfront with annual storage fees of $150 to $300. Donating to a public bank is free, making the stem cells available to any matching patient in need. Key players in the industry include Cord Blood Registry, which has stored over one million units, and Cryo-Cell International, the first private cord blood bank founded in 1989. Other major companies include ViaCord and China Cord Blood Corporation, a significant force in the Asia-Pacific market. Historically, a challenge for treating adults has been the limited number of stem cells in a single cord blood unit. A major breakthrough occurred in April 2023, when the FDA approved Omisirge, the first therapy that involves expanding the number of cord blood stem cells in a lab before transplantation. Beyond cancers and blood disorders, clinical trials are underway to evaluate cord blood stem cells for regenerative medicine applications. Research is actively exploring potential therapies for conditions such as cerebral palsy, autism, type 1 diabetes, and Alzheimer's disease. The practice raises ethical questions concerning informed consent, ownership of the biological material, and equitable access. Due to the low probability of a family ever using privately stored cord blood, the American Academy of Pediatrics recommends public donation unless a family member has a specific medical condition that could be treated by a transplant.